Theme: Epidemiology & Public Health Research Year: 2019
Hepatitis C is very common among people who use drugs (PWUD) and associated with increased
morbidity and mortality. Data regarding the overall and HCV related mortality among PWUD in
Belgium among are scarce. This study aimed to estimate the mortality in a cohort of PWUD as
compared to the general population. Furthermore, the impact of chronic hepatitis C infection on
mortality in PWUD was examined.
Materials and Methods
This retrospective study is based on data concerning 2834 drug users in follow-up at the Free Clinic in
Antwerp. Mortality rates were calculated and compared with a Flemish reference population.
Afterwards mortality was analysed in function of hepatitis C status applying bivariate and survival
A total of 123 patients died during follow-up, resulting in 8.98 deaths per 1000 person-years. The
standardised mortality ratios were 1.38 for men and 3.12 for women. Injecting drug use, older age
and Belgian nationality were associated with a higher mortality but not a positive HCV serostatus.
Unadjusted survival analysis showed a significantly higher survival rate for patients cured after
treatment as compared to chronically infected study subjects (HR = 0.24 (0.08-0.71)). Comparing
spontaneously cleared with chronic patients did not yield a significant difference (HR = 0.57 (0.27-
1.21)). In cox-regression analysis, the lower mortality in successfully treated patients as compared to
chronically infected PWUD remained statistically significant (HR = 0.23 (0.08-0.68)). Spontaneously
cured HCV patients showed a trend towards a lower mortality as compared to chronically infected
PWUD (HR= 0.53 (0.25-1.13)
Mortality rate in PWUD was higher than in the general population especially among women. Our
results suggest a possible positive effect of HCV treatment on survival. However, bias due to a higher
treatment uptake among healthier patients cannot be excluded. More studies involving larger
numbers of patients and a longer follow-up are needed.
Disclosure of interest: Prof Dr Matheï has received funding from MSD and Gilead. No
pharmaceutical grants were received in the development of this study.